STUDY OF BIOCHEMICAL MARKER TARC FOR HODGKIN LYMPHOMA IN HUMAN AND ITS RELATION WITH CLINICO–PATHOLOGICAL BEHAVIOR

Hossam Darwish*, Lamiaa Barakat and Rania Bondok

ABSTRACT

Back ground: Lymphomas can affect any organ in the body and present with a wide range of symptoms and is a curable disease in most patients. In the present study, TARC is the main parameter to prognosis of Hodgkin lymphoma, its positive Hodgkin Reed-Sternberg (HRS) cells has been found in Hodgkin patients. TARC serum levels are significantly high in classical Hodgkin Lymphoma (cHL) patients, so, identification of sensitive biomarker to improve the prognosis related Hodgkin lymphoma is needed. Aim of the work: The aim of the present study was to discuss the prognosis utility of serum TARC in patients for Hodgkin lymphoma during and post therapy the clinical advantage of this marker will be decreased or normal during or post therapy. TARC is a marker used for diagnosis and in follow up the patients for Hodgkin lymphoma. Results: Serum TARC was significantly in most patients for Hodgkin lymphoma. The receiver operating characteristic curve (ROC) curve showed the best cutoff values for TARC was 150 ng / l. Area under the curve of TARC was 0.84, to differentiate patients with complete response from those with partial response. The area under the ROC curve (AUC) was 0.826 with sensitivity 81.3% and specificity 74.4%. To differentiate patients with early stage from those with late stage, the area under the ROC curve was 0.840 with sensitivity 88.0% and specificity 75.0%, and to differentiate patients with B-symptoms from those with no B-symptoms, the area under the ROC curve was 0.860 with sensitivity 86.0% and specificity 75.0%. Conclusion: Results revealed that serum TARC may be used as potential prognostic marker for Hodgkin lymphoma patients.

Keywords: Hodgkin lymphoma patients, thymus and activation-related chemokine (TARC).